Private Wealth Asset Management LLC lifted its position in shares of McKesson Corporation (NYSE:MCK – Free Report) by 141.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,630 shares of the company’s stock after purchasing an additional 955 shares during the period. Private Wealth Asset Management LLC’s holdings in McKesson were worth $1,392,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. purchased a new stake in McKesson during the 2nd quarter worth $8,156,743,000. Bank of America Corp DE boosted its position in McKesson by 2.4% in the 1st quarter. Bank of America Corp DE now owns 1,538,726 shares of the company’s stock valued at $1,331,552,000 after buying an additional 35,916 shares during the last quarter. Boston Partners boosted its position in McKesson by 1.1% in the 3rd quarter. Boston Partners now owns 1,182,796 shares of the company’s stock valued at $1,014,032,000 after buying an additional 13,120 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in McKesson by 3.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 922,573 shares of the company’s stock valued at $697,096,000 after buying an additional 29,747 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of McKesson during the second quarter valued at about $656,566,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on MCK shares. Evercore reaffirmed an “outperform” rating and set a $950.00 target price (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Royal Bank Of Canada lifted their price objective on McKesson from $845.00 to $965.00 and gave the stock a “sector perform” rating in a report on Thursday, November 5th. Mizuho upped their target price on McKesson from $905.00 to $1,020.00 and gave the company a “neutral” rating in a research report on Tuesday, October 20th. UBS Group upped their target price on McKesson from $1,200.00 to $1,250.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Finally, Wells Fargo & Company raised their price target on shares of McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,054.12.
View Our Latest Stock Report on MCK
Key Headlines Impacting McKesson
These are some of the MCK headlines that stood out recently:
- Positive Sentiment: McKesson’s fiscal 2027 second-quarter revenue rose 8% and adjusted EPS increased 18%. Oncology and multispecialty services led growth, while acquisitions and biopharma services support the company’s shift toward potentially higher-margin offerings. Earnings Beat Might Change The Case For Investing In McKesson Stock (MCK)
- Positive Sentiment: Barclays raised its price target on MCK to $1,235, signaling greater potential upside in the firm’s view. McKesson stock: Barclays lifts target to USD 1,235
- Neutral Sentiment: Some coverage highlights positive analyst ratings and raised earnings expectations, but broker recommendations are not guarantees of future performance; valuation and the ability to sustain growth remain important considerations. McKesson (MCK) Dropped, So What Is Driving Attention Now?
McKesson Trading Up 0.7%
Shares of NYSE MCK opened at $1,069.31 on Friday. McKesson Corporation has a twelve month low of $723.68 and a twelve month high of $1,121.50. The company has a market capitalization of $123.46 billion, a price-to-earnings ratio of 27.50, a price-to-earnings-growth ratio of 1.87 and a beta of 0.27. The business has a 50 day simple moving average of $974.65 and a 200-day simple moving average of $880.71.
McKesson (NYSE:MCK – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.72 by $0.96. The firm had revenue of $110.96 billion for the quarter, compared to analysts’ expectations of $109.90 billion. McKesson had a negative return on equity of 202.94% and a net margin of 1.12%. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period last year, the business posted $9.86 earnings per share. As a group, equities analysts predict that McKesson Corporation will post 46.09 earnings per share for the current year.
McKesson Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Tuesday, December 1st will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, December 1st. McKesson’s dividend payout ratio is 9.67%.
Insider Transactions at McKesson
In other news, CAO B Jr sold 111 shares of McKesson stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total value of $98,950.95. Following the completion of the transaction, the chief accounting officer directly owned 521 shares of the company’s stock, valued at approximately $464,445.45. The trade was a 17.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 800 shares of McKesson stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $995.80, for a total transaction of $796,640.00. Following the completion of the transaction, the executive vice president directly owned 5,423 shares of the company’s stock, valued at $5,400,223.40. This trade represents a 12.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 2,161 shares of company stock worth $2,242,515. Insiders own 0.06% of the company’s stock.
McKesson Company Profile
McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers. The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care. Founded in 1833, McKesson serves customers primarily in the United States and Canada.
See Also
- Five stocks we like better than McKesson
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.
